Next Steps

• 2014: After receiving a research grant, the S2I begins commercial development.
• 2015: The ferromagnetic material and electromagnets are the first to be further developed; both reducing their physical size while increasing the amount of attractive force generated.
• 2016: The drugs in the patches are able to penetrate deep into tissue such as muscle and bone.
• 2018: Drug Development: Drug A, a muscle relaxant, and Drug B, a bone softening drug that allows remodeling of bone, begin early drug clinical trials with the properties needed for the S2I. The drug requirements are the following: stability at body temperature, harmful interaction-free, deep penetration into tissue, addiction-free, and local action only.
• 2020: The unit is now self-powered eliminating the need for any electrical back up.
• 2022: The robotic surgical technique for minimally invasive outpatient implantation of ferromagnetic material is perfected.
• 2024: The S2I's control panel, which modulates the frequency, duration, and intensity of the drug, magnetic, and electro stimulation therapies is developed.
• 2026: All therapies are now fully developed, the S2I as a combination medical device is filed with the US FDA for a clinical trial approval.
• 2032: After a successful clinical trial, the S2I is approved for marketing in the USA.
• 2033: First scoliosis patient is treated with the S2I.
• 2038: The five year follow-up of the initial 500 S2I patients show full normal activity, no signs of spinal regression, intense pain, or harmful side effects. There is now a proven robust solution to treat those affected by scoliosis.